Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure

Abstract

SGLT-2 inhibitors reduced the risk of AF in patients with HF, and the effect was consistent irrespective of age, gender, BMI, eGFR, and NYHA classification.